Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Barter

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Circulation|April 6, 2018
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT TrialAntonio J Vallejo-Vaz, Rana Fayyad, S Matthijs Boekholdt, et al.
Journal of the American College of Cardiology|May 17, 2008
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah, David D Waters, Philip Barter, et al.
The American Journal of Cardiology|March 4, 2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)Benoit J Arsenault, S Matthijs Boekholdt, Samia Mora, et al.
Journal of the American College of Cardiology|November 7, 2006
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) studyDavid D Waters, John C LaRosa, Philip Barter, et al.
Atherosclerosis|August 15, 2016
Dyslipidaemia in the Middle East: Current status and a call for actionKhalid Al Rasadi, Wael Almahmeed, Khalid F AlHabib, et al.
Journal of Clinical Lipidology|February 12, 2015
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trialEliot A Brinton, Uma Kher, Sukrut Shah, et al.
International Journal of General Medicine|July 28, 2018
Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle EastMostafa Alshamiri, Mahmood Mohammed Ali Ghanaim, Philip Barter, et al.
Diabetes Research and Clinical Practice|July 12, 2011
Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't knowJuliana C N Chan, Siew Pheng Chan, Chaicharn Deerochanawong, et al.
Journal of Lipid Research|November 23, 2012
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapibMichael Davidson, Sherry Xueyu Liu, Philip Barter, et al.
Lancet (London, England)|September 12, 2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyPrakash Deedwania, Philip Barter, Rafael Carmena, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Circulation|April 6, 2018
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT TrialAntonio J Vallejo-Vaz, Rana Fayyad, S Matthijs Boekholdt, et al.
Journal of the American College of Cardiology|May 17, 2008
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah, David D Waters, Philip Barter, et al.
The American Journal of Cardiology|March 4, 2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)Benoit J Arsenault, S Matthijs Boekholdt, Samia Mora, et al.
Journal of the American College of Cardiology|November 7, 2006
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) studyDavid D Waters, John C LaRosa, Philip Barter, et al.
Atherosclerosis|August 15, 2016
Dyslipidaemia in the Middle East: Current status and a call for actionKhalid Al Rasadi, Wael Almahmeed, Khalid F AlHabib, et al.
Journal of Clinical Lipidology|February 12, 2015
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trialEliot A Brinton, Uma Kher, Sukrut Shah, et al.
International Journal of General Medicine|July 28, 2018
Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle EastMostafa Alshamiri, Mahmood Mohammed Ali Ghanaim, Philip Barter, et al.
Diabetes Research and Clinical Practice|July 12, 2011
Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't knowJuliana C N Chan, Siew Pheng Chan, Chaicharn Deerochanawong, et al.
Journal of Lipid Research|November 23, 2012
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapibMichael Davidson, Sherry Xueyu Liu, Philip Barter, et al.
Lancet (London, England)|September 12, 2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyPrakash Deedwania, Philip Barter, Rafael Carmena, et al.
Pageof 8